1. Home
  2. SFNC vs TARS Comparison

SFNC vs TARS Comparison

Compare SFNC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Simmons First National Corporation

SFNC

Simmons First National Corporation

HOLD

Current Price

$21.33

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$63.87

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFNC
TARS
Founded
1903
2016
Country
United States
United States
Employees
N/A
370
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.7B
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
SFNC
TARS
Price
$21.33
$63.87
Analyst Decision
Buy
Buy
Analyst Count
6
6
Target Price
$22.17
$89.00
AVG Volume (30 Days)
843.4K
638.3K
Earning Date
04-16-2026
05-06-2026
Dividend Yield
4.05%
N/A
EPS Growth
N/A
48.21
EPS
0.47
N/A
Revenue
N/A
$451,360,000.00
Revenue This Year
$2,607.90
$56.43
Revenue Next Year
$4.15
$30.19
P/E Ratio
$45.17
N/A
Revenue Growth
N/A
146.71
52 Week Low
$17.00
$38.51
52 Week High
$22.18
$85.25

Technical Indicators

Market Signals
Indicator
SFNC
TARS
Relative Strength Index (RSI) 56.39 49.22
Support Level $18.65 $60.38
Resistance Level $21.63 $67.24
Average True Range (ATR) 0.42 3.64
MACD -0.04 0.36
Stochastic Oscillator 64.86 67.50

Price Performance

Historical Comparison
SFNC
TARS

About SFNC Simmons First National Corporation

Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. Its loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Share on Social Networks: